The Johns Hopkins Comprehensive Cancer Center is dedicated to research in education and cancer and related disorders and to the prompt application of new knowledge to the treatment of patients and to the prevention of neoplastic diseases. The Johns Hopkins Comprehensive Cancer Center is a multi-disciplinary, interdepartmental center of the Johns Hopkins University. There is a broad base of ongoing cancer research at Johns Hopkins. The specific scientific programs of the Cancer Center are interdisciplinary in character and are focused on human disease. A wide range of activity of encompassed ranging from fundamental research into the molecular genetics of human tumorigenesis to clinical trials of new anti-tumor treatments. The Cancer Center research into the molecular genetics of human tumorigenesis to clinical trials of new anti-tumor treatments. The Cancer Center has established seven major research programs: Cancer Biology, Experimental and Therapeutic Hematopoiesis, Experimental Therapeutics/Solid Tumor Research, Cancer Immunology, Viral Oncology, Cancer Prevention and Control, and Urologic Oncology. Fifteen Shared Resources support the needs of Cancer Center investigators: Cell Sorting and Imaging Core, Animal Resources, Vector Core, Experimental Irradiators, Glassware Washing, Common Equipment, Molecular Pathology Core/Hematologic Malignancy Cell Procurement, Cytogenetics and Molecular Genetics, Pharmacology Analytic, Hematopoietic and Therapeutic Support, Cell and Gene Therapy, Research Pharmacy, Biostatistics, and Clinical Research Office. Interdisciplinary research seminars and research training programs provide valuable opportunities for interdisciplinary interaction and collaboration. Cancer Center developmental founds are used to support faculty recruitment and innovative research; development of shared resources; and a small allocation to pilot projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-43
Application #
6891663
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1978-01-01
Project End
2006-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
43
Fiscal Year
2005
Total Cost
$6,223,765
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225

Showing the most recent 10 out of 2393 publications